If you have been reading about hexenoyl cap and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-25. Numbers and descriptions here follow the published literature rather than marketing material.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
=== Chemical === Darmstadtium is the eighth member of the 6d series of transition metals, and should be much like the platinum group metals. Calculations on its ionization potentials and atomic and ionic radii are similar to that of its lighter homologue platinum, thus implying that darmstadtium's basic properties will resemble those of the other group 10 elements, nickel, palladium, and platinum. Prediction of the probable chemical properties of darmstadtium has not received much attention recently. Darmstadtium should be a very noble metal. The predicted standard reduction potential for the Ds2+/Ds couple is 1.7 V. Based on the most stable oxidation states of the lighter group 10 elements, the most stable oxidation states of darmstadtium are predicted to be the +6, +4, and +2 states; however, the neutral state is predicted to be the most stable in aqueous solutions. In comparison, only platinum is known to show the maximum oxidation state in the group, +6, while the most stable state is +2 for both nickel and palladium. It is further expected that the maximum oxidation states of elements from bohrium (element 107) to darmstadtium (element 110) may be stable in the gas phase but not in aqueous solution. Darmstadtium hexafluoride (DsF6) is predicted to have very similar properties to its lighter homologue platinum hexafluoride (PtF6), having very similar electronic structures and ionization potentials. It is also expected to have the same octahedral molecular geometry as PtF6.
Intracrine signaling is a mode of hormone and growth factor action in which signaling molecules exert their effects within the same cell that produces them, without being secreted into the extracellular environment. The term intracrine was originally coined to describe peptides that either act within the cell that synthesized them or function after being internalized by their target cells. While this model was initially developed through studies on the intracellular action of angiotensin II, it has since been recognized as a fundamental mechanism applicable to numerous peptide hormones and growth factors. Unlike classical endocrine, autocrine, and paracrine signaling, where signaling molecules leave the cell and interact with membrane-bound receptors, intracrine signaling functions exclusively within the intracellular environment, often targeting nuclear or cytoplasmic receptors. This mechanism allows cells to autonomously regulate essential biological functions, including gene expression, differentiation, and survival. One of the most well-characterized examples of intracrine signaling is the local synthesis and action of sex steroids within immune cells, which modulate inflammatory responses and metabolic pathways. The intracrine hypothesis has been instrumental in predicting novel functions for peptide hormones and has generated significant insights with potential therapeutic implications.
== History == BCSIR traces its roots back to the days of East Pakistan. East Regional Laboratories of Pakistan Council of Scientific and Industrial Research (PCSIR) was established in Dhaka in 1955. Subsequently, PCSIR laboratories were established in Rajshahi (1965) and in Chittagong (1967). After the independence of Bangladesh in 1971, BCSIR was established by a resolution of the Government of the People's Republic of Bangladesh which subsequently was reconstituted as the Bangladesh Council of Scientific and Industrial Research through a Presidential Ordinance namely Ordinance No. (V) of 1978.
CD33 has now emerged as the primary target for novel drug discovery programs aimed at curbing neuroinflammation, at over a dozen pharmaceutical and biotech companies. Other AD genes Tanzi has discovered include ADAM10, UBQLN1, IDE, A2M, ITGB3, and ATXN1. In 2020, he used multiple whole genome sequencing datasets for the first time to identify sex-specific genetic risk factors for AD (ZBTB7C, GRID1, RIOK3, MCPH1) as well as several novel Alzheimer's disease-associated rare variants in loci related to synaptic function and neuronal development (FNBP1L, SEL1L, LINC00298, PRKCH, C15ORF41, C2CD3, KIF2A, APC, LHX9, NALCN, CTNNA2, SYTL3, CLSTN2, DTNB, DLG2). In 2022, Tanzi and colleagues whole-genome sequencing to discover two new genes associated with Alzheimer's disease: DTNB and DLG2. Over the past three decades, Tanzi has also contributed to the development of novel therapeutics for AD. In 2000, Tanzi and the late Dr. Steven Wagner discovered a class of Alzheimer’s drugs that they termed "gamma secretase modulators (GSM)". GSM's reverse the Abeta42:Abeta40 ratio and thereby prevent amyloid plaques. Notably, they do not inhibit gamma-secretase. Tanzi and Wagner have published several papers on these compounds. Their GSM is now slated for AD clinical trials in 2026 with Acta Pharmaceuticals. In 2014, Tanzi, and his ex-trainees, Doo Yeon Kim and Se Hoon Choi, were the first to use human stem cells to create three-dimensional cell culture organoids of AD, dubbed by The New York Times as “Alzheimer's-in-a-Dish”.
=== Works cited === Adams, John, ed. (1805). The Annual Register, Or, A View of the History, Politics, and Literature for the Year ... J. Dodsley. Andrew, Christopher (2018). Secret World: A History of Intelligence. Yale University Press. ISBN 978-0-300-24052-8. Arnold, James R. (1995). Napoleon Conquers Austria: The 1809 Campaign for Vienna. Greenwood Publishing Group. ISBN 978-0-275-94694-4. Bell, David Avrom (2007). The First Total War: Napoleon's Europe and the Birth of Warfare as We Know it. Houghton Mifflin Harcourt. ISBN 978-0-618-34965-4. Black, Jeremy (2009). The War of 1812 in the Age of Napoleon. University of Oklahoma Press. ISBN 978-0-8061-4078-0. Briggs, Asa (1959). The Making of Modern England, 1783–1867: The Age of Improvement. Harper & Row. Bryant, Arthur (1944). Years of Victory, 1802–1812. Collins. Burke, Edmund (1808). The Annual Register, Or, A View of the History, Politics, and Literature for the Year ... J. Dodsley. Canales, Esteban (2004), 1808–1814: demografía y guerra en España (PDF) (in Spanish), Autonomous University of Barcelona, retrieved 3 May 2017 Chandler, David G. (1966). The Campaigns of Napoleon. Scribner. ISBN 978-0-02-523660-8. Clodfelter, Micheal (2017). Warfare and Armed Conflicts: A Statistical Encyclopedia of Casualty and Other Figures, 1492–2015 (4th ed.). McFarland. ISBN 978-1-4766-2585-0. Desan, Suzanne; Hunt, Lynn; Nelson, William Max (2013). The French Revolution in Global Perspective. Cornell University Press. ISBN 978-0-8014-6747-9. Dwyer, Philip (2013). Citizen Emperor: Napoleon in Power. Esdaile, Charles (2009).
Sources: en.wikipedia.org
The NIA-AA criteria are used mainly in research rather than in clinical assessments. They define AD through three major stages: preclinical, mild cognitive impairment (MCI), and Alzheimer's dementia. Diagnosis in the preclinical stage is complex and focuses on asymptomatic individuals; the latter two stages describe individuals experiencing symptoms, along with biomarkers, predominantly those for neuronal injury (mainly tau-related) and amyloid beta deposition. The core clinical criteria itself rests on the presence of cognitive impairment without the presence of comorbidities. The third stage is divided into probable and possible AD dementia. In probable AD dementia there is steady impairment of cognition over time and a memory-related or non-memory-related cognitive dysfunction. In possible AD dementia, another causal disease such as cerebrovascular disease is present.
== Criticism and news media portrayal == Since 2013, the term has been adopted by feminists and the media to refer to a misogynist culture within an organization or community. In a New York Magazine article in September 2013, Ann Friedman wrote: "Bro once meant something specific: a self-absorbed young white guy in board shorts with a taste for cheap beer. But it’s become a shorthand for the sort of privileged ignorance that thrives in groups dominated by wealthy, white, straight men." Vox referred to Silicon Valley's "bro culture problem" in its review of Emily Chang's book Brotopia. In 2014 and 2017, Inc published articles on bro culture in business. In its coverage of the 2019 Telegramgate scandal, in which investigative journalists published text messages written by the governor of Puerto Rico, The New York Times referred to "an arrogant 'bro' culture of elites who joked about making chumps out of even their own supporters." The term Bernie Bro, an epithet directed at supporters of Bernie Sanders has been criticized as a reductive smear tactic used by political opponents. The term was widely used because the concept of "bro" itself was vague.
== Function == This type of connective tissue is found mostly in the reticular layer (or deep layer) of the dermis. It is also in the sclera and in the deeper skin layers. Due to a high content of type I collagen, dense irregular connective tissue provides strength, making the skin resistant to tearing by stretching forces from different directions. Dense irregular connective tissue also makes up submucosa of the digestive tract, lymph nodes, and some types of fascia. Other examples include periosteum and perichondrium of bones, and the tunica albuginea of testis. In the submucosa layer, the fiber bundles course in varying planes allowing the organ to resist excessive stretching and distension.
CB2 receptors are predominantly found in the immune system or immune-derived cells, with varying expression patterns. A subpopulation of microglia in the human cerebellum expresses CB2. CB2 receptors are linked to immunomodulatory effects and potential therapeutic benefits in animal models.
Sources: en.wikipedia.org
IonSense, Inc. is a Massachusetts-based company that is developing technology for the analysis of materials by direct analysis in real time or DART mass spectrometry. DART MS provides rapid qualitative and quantitative sample analysis of bioanalytical, medicinal, forensic, and chemical synthesis products by ambient mass spectrometry. IonSense provides the DART Ion Sources which are interfaced to mass spectrometry systems manufactured by JEOL, Thermo Fisher Scientific, Bruker, Applied Biosystems, Agilent, and Waters. IonSense was acquired by Bruker in April 2022.
== External links == International Society for Condensed Matter Nuclear Science (iscmns.org), organizes the ICCF conferences and publishes the Journal of Condensed Matter Nuclear Science. See: library.htm of published papers and proceedings. Low Energy Nuclear Reactions (LENR) Phenomena and Potential Applications Archived 7 October 2015 at the Wayback Machine: Naval Surface Warfare Center report NSWCDD-PN-15-0040 by Louis F. DeChiaro, PhD, 23 September 2015
==== Earlier German rations ==== In the field, the Wehrmacht were provided rations from field kitchens based on the garrison ration. However additional classes of ration were available. The march ration was a cold food ration issued for not more than three or four consecutive days to units in transit either on carrier or by foot. It consisted of approximately 700 grams of bread, 200 grams of cold meat or cheese, 60 grams of bread spreads, 9 grams of coffee (or 4 grams of tea), 10 grams of sugar, and six cigarettes. The ration had a total weight of about 980 grams. An iron ration consisted of 250 grams of biscuits, 200 grams of cold meat, 150 of preserved vegetables, 25 of coffee, and 25 of salt. The total weight of the iron ration was 650 grams without packing and 825 grams with packing. An iron half-ration was composed of 250 grams of biscuits and 200 grams of preserved meat; thus its total weight was 450 grams without packing and 535 grams with packing.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.